The Daily Buyout
$100MDivestiture / carve-outHealthcare & Life SciencesCompleted

Harrow closes TYRVAYA buy from Viatris for up to $100M

Harrow has completed its acquisition of TYRVAYA nasal spray, the first and only FDA-approved nasal spray for dry eye disease, from Viatris. Harrow paid $30 million in cash at closing from cash on hand and may pay up to $70 million in milestones tied to net sales, for potential total consideration of $100 million. Harrow acquired worldwide rights except Japan, where Viatris retains commercialization and will pay royalties.

Why it matters: The deal gives Harrow a second differentiated branded dry-eye product alongside VEVYE in a large and growing U.S. market.

Read the full coverage, free

We only link to sources you can read without a subscription. How we check.

More Healthcare & Life Sciences deals

$5.8BTake-privateHealthcare & Life SciencesOct 7, 2026

CD&R and McKesson to take Option Care Health private for $5.8B

Clayton, Dubilier & Rice and McKesson agreed to acquire Option Care Health for $32.05 per share in a deal valued at about $5.8 billion. CD&R will hold majority ownership, while McKesson invests roughly $1.4 billion for about 49%, with a framework to potentially buy CD&R's stake later. Option Care shares jumped about 34%.

Read at SEC EDGARFree
$2BStrategic acquisitionHealthcare & Life SciencesOct 6, 2026

Shionogi pays $2B for rare disease biotech IntraBio

Japan's Shionogi agreed to acquire Texas-based IntraBio for $2 billion, adding the marketed drug Aqneursa for Niemann-Pick disease type C and Ataxia-Telangiectasia. IntraBio reported sales of $68 million in 2025. The purchase follows Shionogi's acquisitions of Radicava and Tetra Therapeutics as it builds out a rare neurodegenerative disease franchise.

Read at BioPharma DiveFree